---
reference_id: "PMID:31641790"
title: "[Tuberculosis]."
authors:
- Lange C
- Kalsdorf B
- Maurer FP
- Heyckendorf J
journal: Internist (Berl)
year: '2019'
doi: 10.1007/s00108-019-00685-z
content_type: abstract_only
---

# [Tuberculosis].
**Authors:** Lange C, Kalsdorf B, Maurer FP, Heyckendorf J
**Journal:** Internist (Berl) (2019)
**DOI:** [10.1007/s00108-019-00685-z](https://doi.org/10.1007/s00108-019-00685-z)

## Content

1. Internist (Berl). 2019 Nov;60(11):1155-1175. doi: 10.1007/s00108-019-00685-z.

[Tuberculosis].

[Article in German]

Lange C(1)(2)(3)(4), Kalsdorf B(5)(6), Maurer FP(7), Heyckendorf J(5)(6).

Author information:
(1)Medizinische Klinik, Forschungszentrum Borstel, Leibniz Lungenzentrum, 
Parkallee 35, 23845, Borstel, Deutschland. clange@fz-borstel.de.
(2)Tuberkulose Unit, Deutsches Zentrum für Infektionsforschung (DZIF), 
Braunschweig, Deutschland. clange@fz-borstel.de.
(3)Respiratory Medicine & International Health, Universität zu Lübeck, Lübeck, 
Deutschland. clange@fz-borstel.de.
(4)Karolinska-Institut, Stockholm, Schweden. clange@fz-borstel.de.
(5)Medizinische Klinik, Forschungszentrum Borstel, Leibniz Lungenzentrum, 
Parkallee 35, 23845, Borstel, Deutschland.
(6)Deutsches Zentrum für Infektionsforschung (DZIF), Braunschweig, Deutschland.
(7)Nationales Referenzzentrum für Mykobakterien, Forschungszentrum Borstel, 
Leibniz Lungenzentrum, Borstel, Deutschland.

Tuberculosis is a bacterial infectious disease that is usually transmitted by 
inhalation of droplets containing the bacteria. The World Health Organization 
(WHO) estimates that approximately 10 million patients were newly diagnosed with 
tuberculosis in 2017. Rapid diagnosis relies on a combination of imaging and 
microbiological, molecular, and, rarely, immunological tests. Genotypic methods 
enable early diagnosis and allow highly accurate prediction of drug resistance. 
Phenotypic (culture-based) methods are the diagnostic gold standard. Standard 
management of patients with pan drug-susceptible pulmonary tuberculosis includes 
a combination of rifampicin, isoniazid, ethambutol and pyrazinamide for 2 months 
followed by rifampicin and isoniazid for additional 4 months, which leads to 
cure rates of >80%. With individualized treatment schemes, similar cure rates 
can be achieved for patients with multidrug-resistant tuberculosis.

DOI: 10.1007/s00108-019-00685-z
PMID: 31641790 [Indexed for MEDLINE]